Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study

 

• Eliem Therapeutics Inc 
  ELYM+4.61%+ Free Alerts
   announced interim results from its ongoing Phase 1 trial of ETX-155 for major depressive disorder (MDD) and epilepsy. 
• Following lower-than-expected drug exposure levels in the three subjects in a Phase 1b photosensitive epilepsy (PSE) trial, Eliem initiated a Phase 1 trial in healthy subjects to confirm the pharmacokinetic profile of ETX-155.
• ETX-155 demonstrates exposures in single dose 60-milligram cohorts of ongoing Phase 1 pharmacokinetic trial consistent with prior trials. 
• Eliem plans to evaluate a 75-milligram dose of ETX-155 in the repeat dose part of the ongoing Phase 1 pharmacokinetic trial in healthy subjects.
• Final results, including the repeat dose cohort, are expected in Q4 of 2022. 
• The company plans to start the Phase 2a MDD trial in Q1 of 2023, with the topline data expected in mid-2024.
• The company also said it will not reinitiate the PSE proof-of-concept trial but will continue to pursue the development of ETX-155 in focal onset seizures.
• The company is progressing two preclinical candidates from the Kv7.2/3 channel opener program for IND-enabling safety studies, expected in Q1 of 2023, with Phase 1 studies expected to start in 1H of 2024. 
• The company has discontinued the preclinical development of a non-sedating anxiolytic for generalized anxiety disorder because none of the compounds achieved the required profile.
• The company ended the September quarter with a cash balance of $129.8 million, expected to fund operations into 2025.

https://www.benzinga.com/general/biotech/22/10/29153706/eliem-therapeutics-outlines-interim-data-from-early-stage-depressive-study